Discovery of a Potent, Orally Bioavailable β3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide

MLA

Lawrence F. Colwell, et al. “Discovery of a Potent, Orally Bioavailable Β3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2-Hydroxy-2-(3-Pyridinyl)Ethyl]Amino]Ethyl]Phenyl]-4-[4-[4-(Trifluoromethyl)Phenyl]Thiazol-2-Yl]Benzenesulfonamide.” Journal of Medicinal Chemistry, vol. 43, Sept. 2000, pp. 3832–36. EBSCOhost, https://doi.org/10.1021/jm000286i.

APA

Lawrence F. Colwell, William P. Feeney, Liping Deng, Michael J. Forrest, Randy R. Miller, Ralph A. Stearns, Ann E. Weber, Mari R. Candelore, Gary J Hom, D. E. Macintyre, Mathew J. Wyvratt, Dawn Chitty, Robert J. Mathvink, Tolman Js, Laurie Tota, Margaret A. Cascieri, & M. H. Fisher. (2000). Discovery of a Potent, Orally Bioavailable β3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide. Journal of Medicinal Chemistry, 43, 3832–3836. https://doi.org/10.1021/jm000286i

Chicago

Lawrence F. Colwell, William P. Feeney, Liping Deng, Michael J. Forrest, Randy R. Miller, Ralph A. Stearns, Ann E. Weber, et al. 2000. “Discovery of a Potent, Orally Bioavailable Β3 Adrenergic Receptor Agonist, (R)-N-[4-[2-[[2-Hydroxy-2-(3-Pyridinyl)Ethyl]Amino]Ethyl]Phenyl]-4-[4-[4-(Trifluoromethyl)Phenyl]Thiazol-2-Yl]Benzenesulfonamide.” Journal of Medicinal Chemistry 43 (September): 3832–36. doi:10.1021/jm000286i.